Related Experiment Video
Updated: Jun 12, 2026

Characterization of Vascular Morphology of Neovascular Age-Related Macular Degeneration by Indocyanine Green Angiography
Published on: August 11, 2023
[Intravitreal ranibizumab for age-related macular degeneration]
Torben Lykke Sørensen1, Henrik Kemp
1Øjenafdelingen, Sygehus Nord, Roskilde, 4000 Roskilde, Denmark. torbenls@dadlnet.dk
Introduction:
Ranibizumab has improved visual prognosis for patients with age-related macula degeneration (ARMD) complicated with choroidal neovascularisation. We evaluated the results of all our patients within a two-year period.
Material And Methods:
A total of 647 eyes have so far been treated. In all 2,735 injections have been performed.
Results:
Ranibizumab initially increased significantly the best corrected visual acuity from 0.29 to 0.35 (p < 0.001), but after six and 12 months visual acuity stabilized (p = 0.1). We found a positive correlation between initial visual acuity and final visual acuity (p < 0.001). There was a negative correlation between age and final visual acuity (p < 0.001). Complications were rare: one got cataract, we observed a retinal detachment and one choroidal detachment. Other complications were rare and mild.
Conclusion:
Ranibizumab improves visual prognosis in exudative ARMD. Intravitreal injections are safe and complications are rare.
Related Concept Videos
Diabetic Retinopathy
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment